Ding Dong is the Skinny Label (Effectively) Dead?
FDA Law
SEPTEMBER 6, 2021
Teva case, that the statutory provisions governing patent infringement, specifically induced infringement, do not address carve-outs. Instead, it was GSK who erred in omitting the post-MI language from the use code. The catch is, as we have learned from the GSK v. Teva decision changed everything.
52 
Let's personalize your content